原发性胆汁性胆管炎与原发性硬化性胆管炎的治疗格局
本文综述原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)当前及即将出现的治疗方法。PBC一线治疗为熊去氧胆酸,二线或辅助治疗包括奥贝胆酸和贝特类;近期有两种新二线药物获美国食品药品监督管理局批准用于PBC。PSC除肝移植外尚无获批治疗,多种新兴疗法显示鼓舞性结果。
要点
- PBC一线治疗为熊去氧胆酸,二线或辅助治疗包括奥贝胆酸和贝特类。
- 近期两种新二线药物获美国食品药品监督管理局批准用于PBC治疗。
- PSC除肝移植外尚无获批治疗,多种新兴疗法显示鼓舞性结果。
核心结论
- PBC治疗领域正在迅速扩展,近期有两种新二线药物获美国食品药品监督管理局批准,多种其他疗法仍在研究中并显示鼓舞性结果。
- PSC除肝移植外目前尚无获批治疗,但多种新兴疗法已显示鼓舞性结果。
研究设计与样本
- 综述,概述PBC和PSC当前及即将出现的治疗方法。
主要发现
- 熊去氧胆酸历史上是PBC的一线治疗,奥贝胆酸和贝特类用作二线或辅助治疗。
- 近期两种新二线药物获美国食品药品监督管理局批准用于PBC治疗。
- PSC除肝移植外无当前获批治疗,多种新兴疗法显示鼓舞性结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare, and chronic cholestatic diseases that can progress to liver failure. The goals of treatment are to halt the progression of liver disease to cirrhosis and/or liver failure, and alleviate symptoms associated with these diseases. Ursodeoxycholic acid has historically been the first-line treatment of PBC, with obeticholic acid and fibrates used as second-line or adjunctive therapies. However, the treatment landscape is rapidly expanding. Recently, 2 new second-line agents gained US Food and Drug Administration approval for the treatment of PBC, and several other therapies remain under investigation with promising results. Although significant progress has been made in the development of therapies for PBC, there are no current approved treatments of PSC other than liver transplantation although several emerging therapies have shown encouraging results. This review outlines the current and upcoming treatments of PBC and PSC.
引用
- Bhushan S, Sohal A, Kowdley KV, et al. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape. Am J Gastroenterol. 2024. PMID: 39480026. doi:10.14309/ajg.0000000000003174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。